Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TALEN: 5-ALA-SFC in Cardiac Surgery
NCT07027670Phase 2Completed
- Sponsor
- University of Oxford
- Start
- Feb 2021
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of 5-aminolevulinic acid in Myocardial injury (5 arms), sponsored by University of Oxford. Primary endpoints: Change from baseline HO-1 expression to time of cardiac surgery and Number of Participants With Dose Limiting Toxicity. Started Feb 2021; status: completed.
02
Drugs
5-aminolevulinic acid
03
Conditions
Myocardial injury
Beyond the preview
Go deeper on NCT07027670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07027670.